{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:17:55Z","timestamp":1789147075208,"version":"build-2803163510"},"reference-count":9,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T00:00:00Z","timestamp":1463788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005918","name":"Christian Medical College, Vellore","doi-asserted-by":"publisher","award":["22F060"],"award-info":[{"award-number":["22F060"]}],"id":[{"id":"10.13039\/501100005918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2016,11]]},"abstract":"Background & Aim<\/jats:title>Hepatitis B virus\u2010e\u2010antigen (HB<\/jats:styled-content>eAg) is an affordable viral marker to assess viral replication kinetics and response to antiviral therapy. In the absence of confirmatory assays, discrepant or false\u2010positive HB<\/jats:styled-content>eAg results are resolved by screening for other HBV<\/jats:styled-content> markers. We standardized an in\u2010house HB<\/jats:styled-content>eAg neutralization assay (HB<\/jats:styled-content>eAg\u2010NT<\/jats:styled-content>) to confirm HB<\/jats:styled-content>eAg in clinical samples.<\/jats:p><\/jats:sec>Methods<\/jats:title>The performance and reliability of this assay were evaluated by first WHO<\/jats:styled-content> International Standard for HB<\/jats:styled-content>eAg (first WHO<\/jats:styled-content>\u2010IS HB<\/jats:styled-content>eAg) from Paul Ehrlich Institute and clinical samples (n<\/jats:italic>\u00a0=\u00a0150) from chronic HBV<\/jats:styled-content> carriers. Of these, 71 HB<\/jats:styled-content>eAg\u2010positive sera were used for HB<\/jats:styled-content>eAg\u2010NT<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>Concentrations spanning 0.25\u201310\u00a0U of first WHO<\/jats:styled-content>\u2010IS HB<\/jats:styled-content>eAg and clinical samples (S\/Co ranges from 1.00 to 10.00) were neutralized completely in the HB<\/jats:styled-content>eAg\u2010NT<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>HB<\/jats:styled-content>eAg\u2010NT<\/jats:styled-content> is a simple, cost\u2010effective, and reliable direct approach to confirm HB<\/jats:styled-content>eAg in clinical samples which precludes the need for screening additional HBV<\/jats:styled-content> markers in low resource settings.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcla.21995","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T10:50:35Z","timestamp":1464000635000},"page":"1146-1149","source":"Crossref","is-referenced-by-count":2,"title":["Cost\u2010Effective In\u2010House Neutralization Assay for the Confirmation of HB<\/scp>eAg"],"prefix":"10.1002","volume":"30","author":[{"given":"Gnanadurai John","family":"Fletcher","sequence":"first","affiliation":[{"name":"Department of Clinical Virology Christian Medical College Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendran","family":"Anantharam","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology Christian Medical College Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalaivani","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology Christian Medical College Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaldev","family":"Karunakaran","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology Christian Medical College Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology Christian Medical College Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200007)61:3<362::AID-JMV14>3.0.CO;2-I"},{"key":"e_1_2_6_3_1","first-page":"663","article-title":"Sytematic review and meta\u2010analysis of prevalence of hepatitis B in India","volume":"44","author":"Batham A","year":"2007","journal-title":"Indian Pediatr"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24221"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.12.022"},{"key":"e_1_2_6_6_1","first-page":"256","article-title":"Comparison of the Abbott Architect i2000 assay, the Roche Modular Analytics E170 assay, and an immunoradiometric assay for serum hepatitis B virus markers","volume":"37","author":"Kim H","year":"2007","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_6_7_1","first-page":"49","article-title":"Discrepancies between two automated immunoassay systems in determining hepatitis B virus markers in serum samples with concomitant presence of antigens and antibodies","volume":"40","author":"Cheng L","year":"2010","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_6_8_1","unstructured":"AnnetteR.Collaborative study to establish a World Health Organization international standard for Hepatitis B e antigen (HBeAg).World Health Organization;2013; Available from:http:\/\/www.who.int\/iris\/handle\/10665\/96313Last accessed September 8 2014"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.06088.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/clinchem\/46.4.582e","article-title":"Hepatitis B surface antigen: Decreased need for confirmation of reactive results","volume":"46","author":"O'Brien JE","year":"2000","journal-title":"Clin Chem"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.21995","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.21995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T21:16:02Z","timestamp":1696367762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.21995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,21]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/jcla.21995"],"URL":"https:\/\/doi.org\/10.1002\/jcla.21995","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,21]]}}}